Medicamen Biotech profitability ratios
Per cent unless marked ×
| Tap a line for its trend | Last 12Mto Jun 2026 | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
Returns | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |||||
|---|---|---|---|---|---|---|
| 4.0% | 4.0% | 3.4% | 5.6% | 7.7% | ||
| 2.9% | 2.9% | 2.2% | 3.3% | 5.3% | ||
| 4.9% | 4.9% | 3.2% | 7.6% | 8.9% | ||
| 3.3% | 3.5% | 1.9% | 5.1% | 7.7% | ||
Margins | ||||||
| 9.5% | 9.9% | 8.5% | 12.4% | 17.0% | ||
| 6.3% | 6.3% | 4.2% | 8.5% | 12.4% | ||
| — | 15.8% | 49.9% | −6.1% | — | ||
| 6.1% | 6.1% | 6.1% | 7.3% | 12.1% | ||
| 5.0% | 5.0% | 4.0% | 5.3% | 10.5% | ||
| 5.3% | 4.9% | 4.4% | 6.1% | 10.5% | ||
| −19.2% | −19.2% | −5.7% | −3.7% | −9.2% | ||
Additional | ||||||
| 19.2% | 18.3% | 33.7% | 27.4% | 13.6% | ||
| — | 13.8% | 19.4% | 13.3% | 8.6% | ||
| 4.0% | 3.4% | 2.8% | 4.8% | 7.0% | ||
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.